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1. Introduction 
Malignant melanoma is a serious type of skin cancer that begins in the pigmentation system 
of the skin. Malignant melanomas, characterized by their high capacity for invasion and 
metastasis, are one of the most frequent forms of skin cancer. Primary cutaneous melanomas 
have been divided into four groups based on histopathology: superficial spreading 
melanoma, nodular melanoma, lentigo maligna melanoma and acral lentiginious 
melanoma1. Superficial spreading melanoma is the most common type of melanoma and 
grows outwards at first to form an irregular pattern on the skin with an uneven color. It 
usually starts by spreading out across the surface of the skin in what is known as the radial 
growth phase. Nodular melanoma occurs most often on the chest or back. It tends to grow 
deeper into the skin and grows quite deeply if not removed. This type of melanoma is often 
raised above the rest of the skin surface and feels like a bump. It may be very dark brown-
black or black. Lentigo maligna melanoma is most commonly found on the face of elderly 
people. It grows slowly and may take several years to develop. Acral lentiginious melanoma 
is usually found on the palms of the hands, soles of the feet or around the toenails. Although 
melanoma is almost always curable in its early stage, it may be too late if the melanomas 
spread to other parts of the body. Early diagnosis of melanoma is therefore very important, 
and it is necessary to develop additional methods of melanoma therapy2. 
Malignant melanoma usually develops from the transformation and proliferation of 
melanocytes that normally reside in the basal cell layer of the epidermis. It also develops 
when the melanocytes no longer respond to normal control mechanisms of cellular growth. 
The melanocytes may then invade nearby structures or spread to other organs in the body 
(metastasis), where again they invade and compromise the function of that organ. To better 
understand the molecular and cellular mechanisms involved in the progression of 
cutaneous melanoma, human malignant melanoma cells have been widely used as a 
melanoma skin model for in vitro testing. This is because it is highly reproducible, 
quantifiable and easily handled in culture. Not only is it a structural cell model that closely 
parallels the progression of melanoma in vivo, it is also a cost-effective alternative to animal 
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and clinical testing. The antiapoptotic mechanisms regulating cell death have been 
implicated in conferring drug resistance in tumor cells3. Therefore, further knowledge on 
the nature of this resistance and a better understanding of the signal transduction pathways 
leading to tumor cell death could allow the identification of new target molecules to 
overcome drug resistance and improve melanoma therapy. In recent years, toxicogenomics 
has represented the merging of toxicology with genomics and bioinformatics. There have 
been significant practical challenges in pharmacology to develop both predictive and 
mechanism-based toxicology in an effort to identify candidate drugs and toxic agents more 
quickly and economically4. 
Kojic acid (5-hydroxy-2-hydroxymethyl-1,4-pyrone) is a secondary metabolic product 
widely used as a food additive for preventing enzymatic browning of raw crabs and 
shrimps and as a skin lightening or bleaching agent in cosmetic preparations5,6. Kojic acid is 
also used as an important material in antibiotic and pesticide productions and has been 
shown to act as a competitive and reversible inhibitor of animal and plant polyphenol 
oxidases, xanthine oxidase, and D- and some L-amino acid oxidases7,8. Acute or subchronic 
toxicity resulting from an oral dose of kojic acid has never been reported, but convulsions 
may occur if kojic acid is injected. Continuous administration of high doses of kojic acid in 
mice resulted in thyroid adenomas in both sexes9. Moreover, some reports have evaluated 
the tumorigenic potential of kojic acid, and the genotoxic risk for humans using kojic acid as 
a skin-lightening agent has also been studied10. However, kojic acid at high doses has certain 
side effects. For example, it affects thyroid function when given at a massive dose or in a 
long administration period by inhibiting iodine organification in the thyroid, decreasing 
triiodothyronine (T3) and thyroxine (T4) levels and increasing thyroid-stimulating hormone 
(TSH)11. Recently, kojic acid was found to be a tumor promoter and an enhancer of 
hepatocarcinogenesis in rats and in mice12. However, the topical use of kojic acid as a skin-
lightening agent results in minimal exposure that poses a negligible or no risk of 
genotoxicity or toxicity to the consumer. 
Arbutin, a natural compound of hydroquinone beta-D-glucopyranoside, is widely used as 
an ingredient in skin care products13. It is effective in the treatment of various cutaneous 
hyperpigmentations and inhibits melanogenesis in melanoma cells14. However, recent 
findings have raised serious concerns regarding both the safety and side effects of arbutin. 
Although the mechanisms of some inhibitory effects of arbutin on melanogenesis in 
melanoma cells have been elucidated, the comprehensive study of its biological effects on 
the regulation of malignant melanogenesis through the functional effect on carcinogenesis is 
not clear and rarely reported on a human genomics level. The general risk factors for 
melanoma include sun exposure, fair skin that burns easily, blistering sunburn, previous 
melanoma, previous nonmelanoma skin cancer, family history of melanoma, large numbers 
of moles and abnormal moles. During the progression of melanoma, different proteolytic 
enzyme systems, including the plasminogen-activator system and matrix metalloproteinases, 
play an important role in the degradation and remodeling of the extracellular matrix and 
basement membranes15. Tyrosinase is the main enzyme regulating melanogenesis, and it 
catalyzes three distinct reactions in the melanogenic pathway: hydroxylation of monophenol 
(L-tyrosine), dehydrogenation of catechol (L-DOPA) and dehydrogenation of 
dihydroxyindole. By contrast, catalase is the proteolytic enzyme that regulates the removal 
of H2O2, which is a potent inhibitor of tyrosinase. Peroxidase also serves to increase 
eumelanin polymer formation from monomers in the presence of H2O2 and metal ions, 
especially copper, which enhance the conversion of monomers to polymers16. Thus, changes 
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in enzyme levels, including modifications in protein- and gene-expression levels, influence 
melanogenesis in melanomas. The complex regulatory control of the biosynthesis machinery 
involved in melanogenesis also includes receptor-mediated pathways activated by 
hormones, neurotransmitters, cytokines, growth factors and eicosanoids. Additionally, 
receptor-independent mechanisms are activated or modified by nutrients, micromolecules, 
microelements, pH, cation and anion concentrations, and the oxidoreductive potential in the 
physicochemical milieu. Soluble factors can reach target melanocytes by circulation, by 
release from nerve endings or by local production to act as positive or negative regulators of 
melanogenesis. 
Toxicogenomic applications are increasingly used to evaluate preclinical drug safety and to 
explain toxicity associated with compounds at the mechanistic level. Recently, a high-
throughput DNA microarray technique gained an important role in genomic research by 
allowing the simultaneous study of the function of thousands of genes showing differential 
gene expression profiles. This opened the door to the discovery of biomarkers or special 
gene markers intended for pharmaceutical applications and disease therapy17. High-
throughput DNA microarray technology is a powerful tool for genomic research because it 
allows the study of the function of thousands of genes simultaneously, reveals different 
gene expression profiles and elucidates the exact mechanisms and defects in genetic 
aberrations. Recently, microarrays have been used to analyze gene expression profiles of 
human melanomas. However, only a few such analyses have been reported in A375 
melanoma cells. For example, the metastasis of A375 melanoma cells has been studied in 
nude mice by microarray analysis18. 
Proteomics is the study of the proteome, the protein complement of the genome. The terms 
“proteomics” and “proteome” were coined by Marc Wilkins and colleagues in the early 
1990s and mirror the terms “genomics” and “genome,” which describe the entire collection 
of genes in an organism19. In fact, the proteomic approach is a powerful tool for the 
simultaneous determination of the protein composition of complex samples. Proteomics 
consists of several tools, including two-dimensional polyacrylamide gel electrophoresis (2-D 
PAGE) and mass spectrometry20. 2-D PAGE takes advantage of two unique biochemical 
characteristics of proteins, combining isoelectric focusing (IEF), which separates proteins 
according to their isoelectric point, with SDS-PAGE, which further separates them according 
to their molecular mass. 2-D PAGE allows simultaneous detection and quantification of up 
to thousands of protein spots on the same gel21. Mass spectrometry has been in use for many 
years, but it could not be applied to macromolecules such as proteins and nucleic acids. The 
m/z measurements are taken on molecules in the gas phase, and the heating or other 
treatment needed to convert a macromolecule to the gas phase usually caused its rapid 
decomposition. In 1988, two different techniques were developed to overcome this problem. 
In one of the techniques, proteins are placed in a light-absorbing matrix. With a short pulse 
of laser light, the proteins are ionized and then desorbed from the matrix into the vacuum 
system. This process, known as matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI MS), has been successfully used to measure the mass of a wide range 
of macromolecules22. MALDI time of flight (TOF) MS is advantageous due to the rapid and 
direct analysis of complex mixtures and its tolerance to buffer salts or detergents in the 
samples. 
Although the tumorigenic potential and some genotoxic effects of kojic acid and arbutin on 
human skin cell lines have been widely studied, the effect of these compounds on gene and 
protein expression levels that may be involved in many biological functions in human skin 
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has never been reported. In this study, we used DNA microarrays and 2-D PAGE to 
investigate the biological effects of kojic acid and arbutin on gene and protein expression 
profiles of A375 human malignant melanoma cells and on melanocytic tumorigenesis and 
other related side effects of cancer therapy. These candidate genes and proteins may 
consequently aid in the development of early diagnostic and therapeutic applications. 
2. Toxicogenomic analysis of kojic acid-treated A375 melanoma cells 
2.1 Inhibitory effect of kojic acid on A375 melanoma cells 
Previous examination showed that cell growth of A375 melanoma cells was directly 
inhibited by increasing kojic acid concentrations18. After treatment with kojic acid for 72 h, 
the highest concentration of kojic acid (1000 μg/ml) inhibited A375 melanoma cell growth 
less than 40%, whereas the lower concentrations of 0.32, 1.6, 8 and 40 μg/ml kojic acid 
inhibited A375 melanoma cell growth less than 20% (Fig. 1). 
 
 
Fig. 1. Effect of different kojic acid concentrations on the growth inhibition of A375 cells at 
72 h 
These results indicate that the inhibition of A375 melanoma cell growth was not strongly 
affected by all concentrations of kojic acid. In addition, there was no morphological change 
of A375 melanoma cells over 24 h in the presence of 8 μg/ml kojic acid, which is a mild 
concentration and the recommended dosage of kojic acid for human skin safety24. To study 
the early-stage gene expression profile of A375 melanoma cells following stimulation by 
kojic acid, comparable to conditions used in human skin therapy, we chose the 24 h time 
point for the following microarray analysis. 
2.2 Microarray analysis of kojic acid-treated A375 melanoma cells 
Messenger RNA from control and kojic acid-treated A375 melanoma cells was labeled with 
Cy3- or Cy5-dCTP, respectively, using a single round of reverse transcription and 
hybridization with the oligonucleotide microarray chip. The microarray results showed 
different fluorescence intensities of Cy3 and Cy5 depending on the gene expression level18.  
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Table 1. Up-regulated genes (48 genes, ratio > 2.0) in kojic acid-stimulated A375 cells 
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Analysis of gene expression changes at the RNA level using a human 1A oligonucleotide 
microarray complementary to 20,173 60-mer oligonucleotide probes showed a total number 
of 83 differentially expressed genes in kojic acid-stimulated A375 melanoma cells, including 
48 up-regulated genes (Table 1, ratio > 2.0) and 35 down-regulated genes (Table 2, ratio < 0.3). 
We suggest that all of the differentially expressed genes may be regulated by various gene 
networks in the regulation of malignant tumorigenesis. 
2.3 RT-qPCR validation of microarray results 
Genes with a significant change in expression in the array analysis, determined by a mean 
degree of regulation with p<0.01, were chosen for RT-qPCR examination. Differentially 
expressed genes were grouped by biological function correlated with carcinogenesis and the 
significantly changed genes were selected according to the order of P values. The selected 
genes were validated by RT-qPCR analysis to confirm the microarray data. 
RT-qPCR results showed the gene expression levels of seven expressed genes in kojic acid-
stimulated A375 melanoma cells agreed with the DNA microarray expression data18. One 
gene chosen for RT-qPCR examination was the apolipoprotein B RNA editing deaminase 
(APOBEC1) gene25. The comparison of the gene expression level of sAPOBEC1 by 
microarray and RT-qPCR is shown in Table 3. This gene was downregulated in kojic acid-
stimulated A375 melanoma cells and functions as a tumor suppressor in the regulation of 
carcinogenesis. 
3. Toxicogenomic analysis of arbutin-treated A375 melanoma cells 
3.1 Inhibitory effect of arbutin on A375 melanoma cells 
A375 melanoma cell growth was directly inhibited by increasing arbutin concentrations26. 
After 72 h, the highest concentration of arbutin (1000 μg/ml) inhibited A375 cell growth up 
to 40%, while the lower concentrations of 0.32, 1.6, 8 and 40 μg/ml arbutin inhibited cell 
growth by less than 20% (Fig. 2). 
 
 
Fig. 2. Effect of arbutin concentrations on the growth inhibition of A375 cells at 72 h 
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Table 2. Down-regulated genes (35 genes, ratio < 0.3) in kojic acid-stimulated A375 cells 
A375 cell growth was not strongly affected by all arbutin concentrations. In addition, there 
were no morphological changes in cells treated with 0.32-40 μg/ml arbutin. According to 
the safety recommendations for a 1% prescription drug in human skin care products, the 
concentration of 8 μg/ml arbutin is safe and within the recommended concentration27. Also, 
there was no morphological change in the cells within 24 h in the presence of 8 μg/ml 
arbutin, and the inhibition of cell growth was less than 10%. However, the biological effect 
of arbutin on the gene expression profile in A375 melanoma cells and other genotoxic side 
effects have never been reported. Therefore, a purpose of this study was to investigate the 
genotoxic effect of arbutin on human skin and on tumorigenesis. 
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Table 3. Comparison of gene expression levels of the APOBEC1 gene in kojic acid-treated 
A375 cells by microarray and RT-qPCR analysis 
3.2 Microarray analysis of arbutin-treated A375 melanoma cells 
The microarray results show different fluorescence intensities of Cy3 (control) and Cy5 
(arbutin-treated A375 melanoma cells), corresponding to the expression level of thousands 
of genes. The differences in Cy3 and Cy5 signal intensities with a p-value of less than 0.01 
(p<0.01) were considered to be significantly different26. 
 
 
Table 4. Up-regulated genes (32 genes, ratio > 2.0) in arbutin-stimulated A375 cells 
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Analysis of changes in gene expression using the human oligonucleotide array revealed a 
total of 73 differentially expressed genes, including 32 up-regulated genes (Table 4, ratio > 
2.0) and 41 down-regulated genes (Table 5, ratio < 0.3). Therefore, these genes may be useful 
candidate markers for early diagnostic and therapeutic applications of melanoma 
carcinogenesis. 
 
 
Table 5. Down-regulated genes (41 genes, ratio < 0.3) in arbutin-stimulated A375 cells 
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4. Proteomic analysis of kojic acid-treated A375 melanoma cells 
4.1 2-D PAGE of A375 melanoma cells following kojic acid treatment 
To investigate the anticancer effect of kojic acid on the protein expression pattern of A375 
melanoma cells, cells were treated with kojic acid for 24, 48 and 72 h and analyzed by 2-D 
PAGE28. The 2-D gel images of the untreated control and kojic acid-treated A375 melanoma 
cells are shown in Fig. 3. 
Most of the proteins have pI ranges of 3.5-5.0 or 6.5-8.5 with molecular weights of more than 
25 kDa. Using PDQuest image analysis software, approximately 540 spots were detected in 
control and treatment groups with no significant difference of the mean numbers among 
groups. Most of the differentially expressed protein spots have a high molecular weight of 
45-100 kDa, especially at acidic pH. 
 
 
Fig. 3. 2-D PAGE images of A375 human malignant melanoma cells after control (a) and 72 h 
treatment (b) with arbutin. The images in the panels are the regions showing differentially 
expressed spots for protein identification. The pointed arrows indicate the protein spots 
identified in this study 
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To study the biological effect of kojic acid on late-stage protein expression in A375 
melanoma cells, the time point of 72 h was chosen to quantify protein expression changes 
between the control and treatment groups, and the differentially expressed protein spots 
were used to further identify the proteins. There were 30 differentially expressed protein 
spots, including 2 up-regulated protein spots, for which the threshold of change in 
expression level was 1.5-fold, and 28 down-regulated protein spots, for which the threshold 
of change in expression level was 0.9-fold. Seven interesting proteins that have biological 
functions associated with the p53 tumor suppressor protein or are involved in tumor 
biology were then selected for validation by Western blot or RT-PCR. 
4.2 Protein identification of differentially expressed proteins 
With the use of MASCOT protein identification search software for identifying both peptide 
mass fingerprinting (PMF) and MS/MS ion mass data, 30 differentially expressed protein 
spots were successfully identified28. A list of identified proteins, the apparent and theoretical 
MW, pI and fold change in expression level (up- or down-regulation) are shown in Table 6. 
Most of identified proteins were downregulated in kojic acid-treated A375 melanoma cells 
when compared to the control group. There were multiple isoforms of 5 heat shock proteins, 
2 endoplasmin precursors, 2 protein disulfide isomerases, 6 vimentins and 2 aldehyde 
dehydrogenases, which comprised about 56.7% of the identified proteins, which might be 
due to post-translational modifications. In addition, the prediction of protein interaction 
partners is shown in Table 6. The identified proteins were found at different locations within 
the cell. The proteins have diverse functions, especially in protein binding, and play key 
roles in virtually all biological processes, including apoptosis, mammalian cell-cycle 
progression, regulation of angiogenesis, regulation of cell proliferation, regulation of cell 
differentiation and the immune response. Interestingly, 11 identified proteins (36.7% of total 
proteins), including heat shock proteins (HS90B, GRP75, GRP78, ENPL (x2), HSP7C), T-
complex protein 1 subunit epsilon (TCPE), protein disulfide isomerases (PDIA6, PDIA1), 
nucleolin (NUCL) and annexin A11 (ANX11), are chaperone proteins, which were found in 
melanosomes from stage I to stage IV with different functions. 
4.3 Validation by Western blotting and RT-PCR 
Of the identified proteins, GRP75, heat shock protein HS90B, ENPL and pyruvate kinase 
isozyme M1/M2 (KPYM) were validated by RT-PCR, while GRP75, VIME and 
serine/threonine-protein phosphatase 2A (2AAA) were validated by Western blotting  
(Fig. 4). 
Protein and gene expression levels of 7 differentially expressed proteins were in agreement 
with the 2-D PAGE expression data28. The proteins GRP75, VIME, HS90B and ENPL were 
downregulated in kojic acid-treated A375 melanoma cells, while the proteins 2AAA and 
KPYM were upregulated. 
 
5. Proteomic analysis of arbutin-treated A375 melanoma cells 
5.1 2-D PAGE of A375 melanoma cells following arbutin treatment 
The 2-D PAGE images of A375 melanoma cells without treatment (control) and with arbutin 
treatment at 24, 48 and 72 h are shown in Fig. 5. 
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Sopt 
No. 
Protein Name 
Accession 
no. 
Mr 
(Exp) 
pI 
(Exp) 
Mr 
(Cal) 
pI 
(Cal) 
Fold- 
change 
Predicted protein interaction partners 
1 Heat shock protein HSP 90-beta P08238 97.00 4.20 83.2 4.97 -2.50 •TP53/p53 
2 Heat shock 70 kDa protein P11021 91.80 4.20 72.3 5.07 -2.50 •ENPL  •PDIA6  •GRP75  •p53 
3 Endoplasmin precursor (ENPL) P14625 100.00 4.00 92.4 4.76 -1.51 
•GRP75  •GRP78  •PDIA4 receptor 
•Tyrosinase-protein kinase erbB-2 
4 Heat shock cognate 71 kDa (HSP7C) P11142 86.64 4.67 70.85 5.37 -2.00 
•Bcl-2 binding athanogene-1, -3 
•HSP86  •HSP60 
5 
Stress-70 protein, mitochondrial 
precursor (GRP75) 
P38646 89.22 5.10 73.64 5.87 -2.21 
•p53 •DnaJ homologue subfamily A 
and B members  •HSP90B1 
6 
T-complex protein 1 subunit epsilon 
(TCPE) 
P48643 76.32 5.10 59.63 5.45 -2.20 
•T-complex protein 1 different 
subunits 
7 Endoplasmin precursor (ENPL) P14625 68.00 3.95 92.41 4.76 -1.10 
•GRP75  •GRP78  •PDIA4 receptor 
•Tyrosinase-protein kinase erbB-2 
8 
Protein disulfide-isomerase A6 
precursor (PDIA6) 
Q15084 63.00 4.60 48.09 4.95 -2.00 •Beta-Actin  •ERp31  • GRP78 
9 
Protein disulfide-isomerase precursor 
(PDIA1) 
P07237 71.20 4.00 57.08 4.76 -2.10 •ERp31  •GRP78 
10 Nucleolin (NUCL) P19338 102.00 4.00 76.57 4.60 -2.20 
•DNA topoisomerase  •p53 
•Proliferation-associated protein 2G4 
11 Vimentin (VIME) P08670 103.00 4.40 53.62 5.06 -2.25 
•RAF-1  •Proteosome subunit alpha 
type1  •Protein kinase N1 
12 Vimentin (VIME) P08670 58.50 4.25 53.62 5.06 -2.15 
•RAF-1  •Proteosome subunit alpha 
type1  •Protein kinase N1 
13 Vimentin (VIME) P08670 57.00 4.22 53.62 5.06 -2.10 
•RAF-1  •Proteosome subunit alpha 
type1  •Protein kinase N1 
14 Vimentin (VIME) P08670 63.00 4.34 53.62 5.06 -2.10 
•RAF-1  •Proteosome subunit alpha 
type1  •Protein kinase N1 
15 Vimentin (VIME) P08670 62.50 4.40 53.62 5.06 -2.00 
•RAF-1  •Proteosome subunit alpha 
type1  •protein kinase N1 
16 Vimentin (VIME) P08670 61.30 4.30 53.62 5.06 -2.15 
•RAF-1  •Proteosome subunit alpha 
type1  •Protein kinase N1 
17 Gamma-enolase (EC 4.2.1. 11) P09104 58.00 4.17 47.24 4.91 -2.00 
•Pyruvate kinase isoenzyme M1/M2 
•Enzymes in glycolytic pathway 
18 
Pyruvate kinase isozymes M1/M2 
(KPYM) 
P14618 71.16 4.40 57.90 7.96 +2.15 
•Alpha enolase  •Beta enolase 
•Pyruvate dehydrogenase E1 subunits 
19 
Serine/threonine-protein phosphatase 
2A 65 kDa regulatory subunit A alpha 
isoform (2AAA, PP2A) 
P30153 76.30 4.25 65.18 4.96 +1.52 
•RAF proto-oncogene serine/threonine 
kinase  •Serine/threonine protein 
phosphatase isoforms 
•Protein KIAA0889 
20 Ribonuclease inhibitor (RINI) P13489 58.50 3.90 49.94 4.71 -2.18 
•TNF-α  •TNF-R1 
•NF-kappa-B-essential modulator 
21 Tubulin beta chain (TBB5) P07437 65.00 4.40 49.64 4.78 -0.99 
•Kinesin-like protein (KIF1A) 
•Mitogen-activated protein kinase 10 
•Dual specificity protein kinase TTK 
22 
Melanoma-associated antigen 4 
(MAGA-4) 
P43358 55.00 3.90 34.91 4.68 -2.30 
•26S proteosome regulatory subunit 
p28  •B melanoma antigen 3 
precursor  •Cancer/testis antigen 2 
23 
Annexin A11 (Calcyclin-associated 
annexin 50) (ANX11) 
P50995 71.20 6.18 54.36 7.53 -1.55 
•Programmed cell death protein 6 
•40S ribosomal protein 24  
•Calcyclin •DNA-directed RNA 
polymerase III 
24 
Eukaryotic translation initiation factor 
3 subunit 2 
Q13347 48.00 5.10 36.48 5.38 -1.00 
•Eukaryotic translation initiation 
factor subunits 
25 
60S acidic ribosomal protein P0 
(RLAO) 
P05388 45.50 5.15 34.25 5.71 -0.95 
•Ribosomal proteins 
•Elongation factor 1-gamma 
26 
Inosine-5’monophosphate 
dehydrogenase 2 (EC 1.1.1.205) 
(IMDH2) 
P12268 71.16 6.00 55.77 6.44 -2.00 
•Inosine-5’monophosphate 
dehydrogenase 1  •GMP synthase 
•GMP reductase 1 and 2 
•AMP deaminase 1 and 3 
27 
Aldehyde dehydrogenase 1A3 (EC 
1.2.1.5) (AL1A3) 
P47895 72.00 6.25 56.07 6.99 -1.02 
•3-Hydroxyisobutyrate dehydrogenase 
•Acetyl-coenzyme A synthetase 2-like 
28 
Aldehyde dehydrogenase 1A3 (EC 
1.2.1.5) (AL1A3) 
P47895 72.00 6.35 56.07 6.99 -0.99 
•3-Hydroxyisobutyrate dehydrogenase 
•Acetyl-coenzyme A synthetase 2-like 
29 
ATP synthase subunit beta, 
mitochondrial precursor (EC 3.6.3.14) 
P06576 64.00 4.50 56.52 5.26 -1.00 
•ATP synthase isoforms 
•NADH-ubiquinone oxidoreductase 
30 
Rab GDP dissociation inhibitor alpha 
(Rab GDI alpha) 
P31150 76.32 4.30 50.55 5.00 -0.97 
•RAB4A  •RAB5A  •RAB2 
•RAB11A •RAB9A  
Table 6. Protein identification of differentially expressed proteins in kojic acid-treated A375 
cells and the prediction of protein interaction partners 
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Fig. 4. Validation of differentially expressed proteins by Western blot and RT-PCR analyses. 
RT-PCR of (a) GRP75, (b) 2AAA, (c) HS90B (d) ENPL and (e) KPYM. Western blot of 
(f) GRP75, (g) VIME, and (h) 2AAA. c1, c2 and c3 indicate the control groups at 24, 48 and  
72 h, respectively. d1, d2 and d3 indicate the treatment groups at 24, 48 and 72 h, respectively 
The molecular weights of the proteins were distributed within the range of 25 to 97 kDa, and 
the differentially expressed protein spots had isoelectric points distributed between acidic 
and basic pH29. Using PDQuest image analysis software, approximately 540 spots were 
found in the control and treatment groups with no significant difference between the 
groups. There were 40 differentially expressed protein spots, including 10 up-regulated 
protein spots with a threshold of change in expression level of 1.0-fold, and 40 down-
regulated protein spots with a threshold of change in expression level of 0.9-fold. 
5.2 Identification of differentially expressed proteins 
Using the MASCOT protein identification search software for identifying both PMF and 
MS/MS ion mass data, 26 differentially expressed proteins were successfully identified29. 
Among these proteins, there were five up-regulated and 15 down-regulated proteins 
(including their isoforms). Most of the identified proteins were downregulated in arbutin-
treated A375 melanoma cells, and 13 isoforms of six identical proteins were observed. There 
were two vimentins, two heterogeneous nuclear ribonucleoproteins A2/B1, two 
heterogeneous nuclear ribonucleoproteins A1, two peroxiredoxin-1 proteins, three 
glyceraldehyde-3-phosphate dehydrogenases and two alpha-enolases, accounting for about 
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Fig. 5. 2-D PAGE images from A375 human malignant melanoma cells under the following 
conditions: (a) control, (b) 24-h arbutin treatment, (c) 48-h arbutin treatment and (d) 72-h 
arbutin treatment. The samples were separated on a homogeneous 12.5% SDS-PAGE gel 
using a pH 3–10 NL IPG strip. The pointed arrows indicate the protein spots identified in 
this study 
50% of all identified proteins possibly due to post-translational modifications. The protein 
interaction partners are also predicted. The identified proteins are distributed to many 
locations within the cell, have diverse functions and play important roles in many biological 
processes, especially in cancer biology, such as apoptosis, angiogenesis, cell proliferation, 
cell differentiation and the immune response. Interestingly, five identified proteins, heat 
shock protein 90 kDa beta member 1 (ENPL), voltage-dependent anion-selective channel 
protein 1 (VDAC-1), chloride intracellular channel protein 1 (CLIC1), guanine nucleotide-
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binding protein subunit beta (GBLP) and 14-3-3 protein gamma (14-3-3G) (19% of total 
proteins), were found to play important roles in apoptosis and signal transduction. 
Additionally, six identified proteins (nine spots including their isoforms, 34.6% of total 
proteins), nuclear ribonucleoprotein H (HNRH1), ribonucleoproteins A2/B1 (ROA2), 
ribonucleoprotein A1 (ROA1), ribonuclease inhibitor (RINI), 14-3-3G and alpha-enolase 
(ENOA), function in nucleic acid processing or transcriptional regulation. Moreover, four 
identified proteins (seven spots including their isoforms, 27% of total proteins), malate 
dehydrogenase (MDHM), glyceraldehyde-3-phosphate dehydrogenase (G3P), glucose-6-
phosphate 1-dehydrogenase (G6PD) and ENOA are involved in carbohydrate metabolism 
pathways and have additional functions in the regulation of cell growth and maintenance of 
cellular functions. 
5.3 Validation by Western blot or RT-PCR 
Of the identified proteins, vimentin (VIME), 14-3-3G, peroxiredoxin-1 (PRDX1), ENPL, 
inosine-5’-monophosphate dehydrogenase 2 (IMDH2), ENOA, VDAC-1 and p53 were 
validated by RT-PCR (Fig. 6). The protein and gene expression levels of eight differentially 
expressed proteins were in agreement with the 2-D PAGE expression data29. 14-3-3G, 
VDAC-1 and p53 were upregulated in the arbutin-treated A375 melanoma cells, whereas 
VIME, PRDX1, ENPL, IMDH2 and ENOA were downregulated in the arbutin-treated A375 
melanoma cells. 
 
 
Fig. 6. Validation of differentially expressed proteins by RT-PCR analyses. (a) ǃ-actin,  
(b) VIME, (c) ENPL, (d) 14-3-3G, (e) VDAC-1, (f) ENOA, (g) PROX1, (h) IMDH2 and (i) p53. 
C1, C2 and C3 indicate the control group at 24, 48 and 72 h, respectively. 1d, 2d and 3d 
indicate the treatment groups at 24, 48 and 72 h, respectively 
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6. Discussion 
Although some of the biological applications and potential effects of kojic acid have been 
partially elucidated30, the effects of kojic acid on a human genomics level, including gene 
regulatory mechanisms, are not clear and has rarely been reported. In this study, we used 
A375 human skin malignant melanoma cells to examine the genotoxicity of kojic acid in 
carcinoma therapy, not including its skin-whitening effect. To examine the genotoxicity 
effect of kojic acid on the gene expression profile of A375 melanoma cells, microarray 
technology providing a high-throughput method for easily screening the number of 
differentially expressed genes was used. It has been used for analysis of gene expression in 
dermatological studies, including studies of human melanomas31. However, the study of 
gene expression in kojic acid-stimulated A375 melanoma cells by DNA microarray has 
never been reported. It is challenging to use the high-throughput technology of DNA 
microarray for studying the effect of kojic acid on the large numbers of differentially 
expressed genes in A375 melanoma cells and its anti-tumorigenic function to regulate the 
malignancy of melanoma. We used the human 1A oligonucleotide microarray to analyze 
gene expression of human skin A375 melanoma cells for the following reasons: (i) the 
human 1A oligonucleotide microarray is comprised of 20,173 oligonucleotide probes that 
span conserved exons across transcripts of 18,716 human genes, is compatible with human 
skin A375 melanoma cells and could screen large numbers of differentially expressed 
human genes at a single time. (ii) The human 1A oligonucleotide microarray uses a 
convenient two-color labeling procedure that reduces experimental variability by allowing 
biological samples to be directly compared with each other on the same microarray after 
undergoing the same hybridization incubation. This microarray platform allowed the 
analysis of kojic acid-responding genes in A375 melanoma cells that may be used as gene 
markers of malignant melanoma for diagnostic and therapeutic applications in human skin. 
We examined the effect of various concentrations (0.32, 1.6, 8, 40, 200 and 1000 μg/ml) of 
kojic acid on growth inhibition of A375 melanoma cells. Not all kojic acid concentrations 
strongly inhibited the cell growth of A375 melanoma cells, even at the longer incubation 
time of 72 h. When using microarray technology to study the overall effects of kojic acid on 
gene expression of A375 melanoma cells, we used 8 μg/ml (0.8%) kojic acid because this is 
the mildest concentration that could inhibit A375 melanoma cells less than 20% while 
avoiding potential differences in gene expression data resulting from the cell death response 
due to cytotoxicity from higher concentrations of kojic acid. The safe level of kojic acid in 
human skin care products for general use is up to 1% without a prescription24. Therefore, 8 
μg/ml kojic acid (0.8%) is safe for human skin and can be used to study the gene expression 
profile of A375 melanoma cells and identify the regulatory functions of these genes in 
carcinogenesis therapy. After microarray data were collected, we used bioinformatic tools to 
identify the differentially expressed genes and searched Gene Ontology for useful 
information. The information obtained can be used to further study regulatory mechanisms 
and gene markers for applications in early cancer diagnosis and therapy. For a number of 
differentially expressed genes, we selected significant genes involved in carcinogenesis and 
compared microarray analysis data with RT-qPCR data to validate changes in gene 
expression. RT-qPCR offered confirmatory quantitative results under stringent conditions. 
We show the quantification of kojic acid-responding genes from RT-qPCR is in agreement 
with the DNA microarray expression data. This indicates that the validation of genes in the 
robust biomarkers lists was done using precise data. These validated genes may become 
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useful biomarkers to understand the biochemistry of a drug/small molecule response in 
future clinical studies. Interestingly, we have found seven significant kojic acid-responsive 
genes downregulated in kojic acid-stimulated A375 melanoma cells. Most of the genes are 
related to the regulation of carcinogenesis. Apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 1 (APOBEC1), is the central component of an RNA editosome, whose 
physiological role is the deamination of apoB mRNA cytidine-6666 to uracil in 
gastrointestinal tissues, thereby creating a premature stop codon32. Uncontrolled cytidine 
deamination could generate inappropriately folded polypeptides, dominant-negative 
proteins, or mutations in tumor suppressor genes and thus contribute to tumor formation33 . 
Overexpression of APOBEC1 has led to the development of a number of different cancers, 
such as gastrointestinal cancer, colon cancer and heptocellular cancer, in a variety of tissues. 
This implies that inappropriate expression of a member of the DNA deaminase family could 
have potential oncogenic activity34. Furthermore, most human carcinomas are caused by 
APOBEC1-mediated mRNA editing35. Thus, down-regulated APOBEC1 may potentially 
deactivate the tumor progression of A375 melanoma cells. 
In conclusion, we used high-throughput DNA microarray and RT-qPCR techniques for the 
global analysis of differentially expressed genes responding to kojic acid in A375 human 
melanoma cells. The differentially expressed genes were classified depending on cellular 
localization, molecular function and biological process, and they led to an exploration of the 
more valuable data on the regulation of melanoma carcinogenesis against kojic acid. In 
addition, seven of the down-regulated genes that showed significantly different expression 
in A375 melanoma cells after kojic acid treatment function as tumor suppressors and may 
disrupt the regulation of melanoma tumorigenesis in human malignant melanoma cells. 
These genes may be useful markers in further diagnostic and therapeutic applications. 
Moreover, our findings show the probable side effects and disadvantages of kojic acid due 
to its effect on the immune system, bone development and maintenance. However, we will 
further study the effects of kojic acid on biological and molecular mechanisms in human 
melanoma skin cells, including in other parts of the body, and also examine other biological 
functions of kojic acid in its cosmetic and/or therapeutic applications. We also examined the 
effect of different arbutin concentrations on the growth inhibition of A375 melanoma cells 
and found that the concentrations used did not strongly inhibit cell growth, even though the 
incubation time was up to 72 h. We used 8 μg/ml (0.8% w/v) arbutin because (i) this was 
the same concentration of kojic acid used18, because this concentration was lower than the 
safety recommendation of 1% in prescription human skin care products36; (ii) this 
concentration inhibited cell growth less than 10% with no morphological change of cells; 
and (iii) it avoids changes in gene expression data resulting from the cell death response due 
to cytotoxicity from a high concentration of arbutin. Therefore, 8 μg/ml arbutin, which is 
safe for use on human skin, was used to study the genotoxic effect on the gene expression 
profile of A375 melanoma cells and for examining the differential gene expression and other 
side effects of altered signaling pathways for cancer therapy. To study the effect of arbutin 
on the gene expression level of A375 melanoma cells, RNA was isolated from cells 24 h after 
arbutin treatment to study gene expression levels with microarray analysis. 
We also used high-throughput DNA microarray and bioinformatic tools in a global analysis 
of differentially expressed genes in arbutin-treated A375 malignant melanoma cells. These 
genes were classified by Gene Ontology and led to an exploration of more valuable data on 
the regulation of melanoma carcinogenesis. In addition, four down-regulated genes are 
candidate tumor suppressor genes in A375 melanoma cells following arbutin treatment. 
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They may disrupt the regulation of malignant tumorigenesis in human malignant 
melanoma cells and may be useful markers for further diagnostic and therapeutic 
applications. Moreover, the genotoxic effect of arbutin on the gene expression profile of 
A375 melanoma cells was similar to kojic acid, which indicates a similar regulation of 
malignant tumorigenesis by these drugs. However, we will conduct further studies on the 
effects of arbutin on biological and molecular mechanisms in human skin cells. We will also 
examine other biological characteristics of arbutin for therapeutic applications. According to 
our study investigating the toxicogenomic effects of kojic acid on the gene expression profile 
of A375 melanoma cells using microarray analysis, the cell growth inhibition was not 
strongly affected by all concentrations of kojic acid at a longer treatment time of 72 h18. 
There was no morphological change of A375 melanoma cells over the 72 h exposure to 8 
μg/ml kojic acid, which is a mild concentration and the recommended safe dose of kojic 
acid for human skin. The early stage of the kojic acid stimulatory effect on the gene 
expression profile of A375 melanoma cells also uncovered some tumor suppressor genes. 
Although one gene makes one protein, protein modifications leading to changes in 
biological and physiological functions may not be caused by gene modifications. To examine 
the effects of kojic acid on protein expression levels in A375 melanoma cells, the same 
concentration of kojic acid (8 μg/ml) as in the microarray study, which is compliant with the 
safety recommendation in human skin care products, and various treatment times (24, 48 
and 72 h) were used in this study. 2-D PAGE identified 30 differentially expressed proteins 
that showed a significant change in expression levels following 72 h of drug treatment. We 
used combined databases to propose a protein interaction network in which 16 differentially 
expressed proteins are involved in the regulation of apoptosis via major signaling proteins, 
such as p53, Ras, MEK/ERK, RAF-1 and Bcl-2. Interestingly, 11 chaperone proteins were 
downregulated in kojic acid-treated A375 melanoma cells and were found to interact with 
each other. It is well known that heat shock proteins are required for cell survival during 
stress and also have key functions in controlling cellular metabolism37. In cancer biology, 
heat shock proteins are expressed at high levels during facilitated tumor cell growth and 
survival38. In addition, GRP75, GRP78 and HSP90 interact with the p53 tumor suppressor39. 
HSP90B has a principal role in the regulation of mitogenesis and cell cycle progression and 
could interact with HSP70 or GRP75 to participate in the protein degradation process and 
protection from programmed cell death. HSP7C interacts with the Bcl-2 binding proteins 
athanogene-1 and athanogene-3 and other chaperone proteins, including HS90B and ENPL. 
According to our results of down-regulated heat shock proteins in kojic acid-treated A375 
melanoma cells, cellular stress in malignant melanoma cells was observed following kojic 
acid treatment. Kojic acid could suppress the expression of heat shock proteins, which 
support tumor growth and may lead to an antiapoptosis effect. Alternatively, because a 
primary mechanism for the regulation of heat shock proteins in normal cells involves the 
tumor repressor p53 and the related protein p63, the downregulation of heat shock proteins 
may be involved in the suppression of p53 expression. It has also been reported that p53 and 
p63 proteins suppress the transcription of heat shock protein-encoding genes via their 
promoter binding sites for the transcription factor NF-Y40. The suppression of heat shock 
protein expression by kojic acid may play an important role in its antitumor activity. The 70-
kDa heat shock cognate protein (HSP7C) is a member of the HSP70 heat shock protein 
family. HSC/HSP70 function is regulated by the chaperone Bcl-2-associated gene product-1 
(BAG-1), which acts as a coupling factor between HSC/HSP70 and a proteasome 
component41. BAG-family proteins also contain the BAG-domain, which mediates a direct 
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interaction with HSP70, the ATPase domain and a number of client proteins, including the 
protein kinase Raf-142. Raf-1 is an important signaling molecule that functions in the Ras 
pathway to transmit mitogenic, differentiative and oncogenic signals to the downstream 
kinases MEK and ERK43. According to the BioCarta pathway of melanogenesis, Raf-1, Ras, 
MEK and ERK are important regulatory proteins in melanocytes. HSP70 also has an 
important role in the cotranslational maturation pathway of the human type I membrane 
glycoprotein tyrosinase, which interacts with calreticulin and BiP/Grp78 during its ER 
transit44. Thus, the HSP7C associated with heat shock proteins can interact with regulatory 
molecules in the melanogenesis pathway, in which these proteins are upstream regulators of 
other melanogenic enzymes, including tyrosinase and tyrosinase related protein-1. 
The protein phosphatase 2AAA (or PP2A) was found to interact with 
hyperphosphorylated/desensitized Raf-145. 2AAA is required for recycling of Raf-1 to an 
activation-competent state and for melanosome aggregation, and it interacts with p53, Raf-1 
and Bcl-2. 2AAA is also a major Ser/Thr phosphatase implicated in the regulation of many 
cellular processes, including many signal transduction pathways and cell-cycle 
progression46. In cancer cells, 2AAA has been proposed to negatively regulate cellular 
growth and might function as a tumor suppressor47. Confirmation by Western blot analysis 
showed 2AAA is upregulated in kojic acid-treated A375 melanoma cells at 48 and 72 h. It 
has been suggested that kojic acid may stimulate the expression of 2AAA, leading to 
suppression of signaling molecules in melanogenesis. According to 2-D gel analysis, 6 
isoforms of vimentin were downregulated in kojic acid-treated A375 melanoma cells. It is 
well known that vimentin regulates cell migration, membrane trafficking, granular 
secretion, protein kinase activation and regulation of stress response proteins48. The 
modification of vimentin isoforms might be caused by phosphorylation, which has a central 
role in regulating the dynamics of vimentin assembly into polymers as well as in regulating 
the connections between intermediate filament (IF) and IF-associated proteins49. There are 
many phosphorylation events affecting vimentin. For example, phosphorylation by Raf-1-
associated vimentin kinase results in the proper structure of vimentin filaments50 and 
phosphorylation by protein kinase C (PKC) creates isoforms that participate in the 
regulation of organelle movement in melanophores and many signal transduction pathways 
involving tyrosine kinase, nucleotide exchange factor, serine/threonine kinase, Raf-1, PKC, 
cytoskeletal protein actin, proteosome component and HSC7051. In addition to 
phosphorylation, the different spots of vimentin seen on the 2-D gel may be due to 
association with other molecules, such as protein kinase C, integrin or other associated 
proteins in signal transduction pathways. Changes in vimentin expression levels are also 
generated by stress, such as heat shock and oxidative stress52. Cleavage of vimentin 
precedes the recognition of cytoskeletal filaments in apoptosis and programmed cell death 
mechanisms. Downregulation of vimentin expression inhibits migration and invasion of 
colon and breast cancer cell lines53. According to our Western blot analysis, down-regulated 
vimentin may suppress tumorigenesis and regulate apoptosis in kojic acid-treated A375 
melanoma cells. Moreover, the presence of more than one protein band recognized by the 
monoclonal antibody of vimentin may be caused by post-translational modifications. 
Another protein that leads to tumor suppression is pyruvate kinase isoenzyme (KPYM). It is 
a key sensor for energy consumption and regulation of the glycolytic pathway, in which 
KPYM links energy-rich metabolites from the flow of glucose carbons to nucleic acid54. In 
yeast cells, overexpression of pyruvate kinases leads to an inhibition of cell proliferation by 
depletion of glycolytic phosphometabolites. Likewise, pyruvate kinases in eukaryotic cells 
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are involved in such fundamental processes as cell proliferation, tumor formation and 
apoptosis55. Energy used by cancer cells is preferentially produced from glycolysis, in which 
p53 was found to modulate the balance between the utilization of the respiratory and 
glycolytic pathways56. According to our results from 2-D PAGE and Western blot data, 
KPYM upregulated in kojic acid-treated A375 melanoma cells may play an important role in 
the suppression of tumor growth and metastasis. In summary, we identified a number of 
differentially expressed proteins in kojic acid-treated A375 melanoma cells. Most of these 
proteins were key factors involved in a wide variety of cellular processes, including cell 
proliferation, regulation of gene expression, signaling, and chromatin and cytoskeleton 
organization. Interestingly, our proposed interaction network reveals proteins associated 
with the regulation of apoptosis, which may lead to suppression of the melanogenesis and 
tumorigenesis of cancer cells. Moreover, these proteins may be useful biomarkers for use in 
diagnostic and therapeutic applications of skin cancer. Further functional studies of these 
proteins may lead to better understanding of the pathogenic mechanisms and cellular 
response to kojic acid treatment. 
According to our investigation of the toxicogenomic effects of arbutin on the gene 
expression profile of A375 melanoma cells using microarray26, there was no growth 
inhibition or morphological change of A375 melanoma cells after 72 h in the presence of 8 
μg/ml arbutin, which is a mild arbutin concentration and safe for human skin. The gene 
expression data showed some tumor suppressor genes as biomarkers in A375 melanoma 
cells. Although one gene makes one protein, post-translational modifications of proteins can 
lead to changes in biological and physiological functions that may not result from gene 
modification. To examine the effects of arbutin on protein expression levels in A375 
melanoma cells, the same concentration of arbutin (8 μg/ml) at different treatment times of 
24, 48 and 72 h was used. Among the differentially expressed proteins validated by RT-
qPCR, VIME, 14-3-3G and VDAC-1 were found to interact with Raf-1. VIME, an IF protein, 
is the major cytoskeleton component of developing cancer cells. VIME is phosphorylated by 
Raf-1-associated vimentin kinase, resulting in the regulation of the vimentin filament 
structure57. VIME is also a target for phosphorylation by PKC, which is involved in many 
signal transduction pathways including the regulation of organelle movement in 
melanophores58, cytoskeletal function and programmed cell death (apoptosis)59. In 
carcinoma cell lines, downregulation of VIME expression resulted in impaired migration 
and adhesion60. Likewise, our RT-qPCR results show that VIME is downregulated in 
arbutin-treated A375 melanoma cells, suggesting an effect on the IF network that ultimately 
leads to impaired migration and adhesion of A375 melanoma cells. Because VIME is 
involved in the regulation of stress response proteins61, the heat shock protein ENPL, also 
found to be downregulated in A375 melanoma cells in this study, may be involved in VIME 
regulation. ENPL is a member of the heat shock protein HSP90 complex found in the 
melanosome. It is well known that heat shock proteins are overexpressed in a wide range of 
human cancers and are implicated in tumor cell proliferation, differentiation and 
recognition by the immune system62. Therefore, the ENPL downregulated in arbutin-treated 
A375 melanoma cells may suppress tumor progression and metastasis and cause the 
decreased immune response. 
ENPL was also found to be associated with other types of heat shock proteins and interacts 
with p53 and 14-3-3 proteins, both of which play important roles in apoptosis. 14-3-3 
proteins act as control points for many cellular processes and therefore play significant roles 
in cell-fate determination and in several apoptotic pathways in animals63. 14-3-3 proteins 
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have been reported to have important interactions with other regulatory proteins. They 
display important anti-apoptotic characteristics by inhibiting the pro-apoptotic Bcl-2-
antagonist of cell death (BAD) and the transcription factor FKHRL-1. Major roles ascribed to 
the mammalian 14-3-3 proteins include activation of tyrosine and tryptophan hydroxylases, 
regulation of PKC, exocytosis, especially in mediating interactions between protein kinases, 
and other signal transduction proteins64. 14-3-3 was found to activate the Ras-Raf mitogenic 
pathway and can elicit a physiologically significant activation of Raf-1 in mammalian cells65. 
Because 14-3-3 proteins are involved in a great number of interactions, the effects of 
knocking out or overexpressing specific 14-3-3 genes or 14-3-3 target genes will likely have 
effects on other 14-3-3-regulated cellular processes. Studies have found that 14-3-3 proteins 
activate p53 function in vivo; thus, the up-regulation of 14-3-3G protein expression in 
arbutin-treated A375 melanoma cells implies that arbutin can stimulate changes in signal 
transduction pathways by stabilizing or increasing the expression of 14-3-366. The increase in 
protein expression might involve a critical response of cell proliferation, differentiation and 
apoptosis of arbutin-treated A375 melanoma cells. The change in the expression of 14-3-3 
might alter the biological activities of p53, RAF-1, CLIC1, ENPL, Bcl2 and kinesin-like 
proteins. Interestingly, the partial functions of ENPL and VDAC-1 on ion channel activity 
and ion sequestering ability are involved in energy metabolism, which is important for 
survival. The cellular location of these proteins at the cell membrane and mitochondria 
implies that the effect of arbutin on membrane and mitochondria may cause changes in 
cellular physiology and metabolic events. VDAC-1, a major mitochondrial outer membrane 
transporter, is a component of the permeability transition (PT) and plays an important role 
in apoptosis by participating in the release of intermembrane space proteins, including 
cytochrome c, and by its involvement in Ca2+ signaling67. VDAC-1 has also been found to be 
associated with the Bax/Bak and Bcl-2 families of proteins, which are essential regulators of 
cell death and exert their primary pro- or anti-apoptotic roles at the mitochondrial outer 
membrane. Therefore, the upregulation of VDAC-1 expression in arbutin-treated A375 
melanoma cells may play a crucial role in mitochondria-mediated apoptosis, mitochondrial 
membrane permeability transition and intracellular Ca2+ transport. Alternatively, p53 tumor 
suppressor proteins have been reported to have additional roles in the regulation of 
glycolysis. 
In this study, four proteins identified as glycolytic enzymes, G3P, ENOA, G6PD and 
MDHM, were found to be involved in glucose metabolism, but only ENOA was validated 
by RT-PCR. The low expression of ENOA in arbutin-treated A375 melanoma cells may be 
implicated in metastasis and may also change the associated signaling pathways that 
modulate cellular metabolism. In addition to regulating glycolysis in cancer cells, p53 also 
helps to regulate both apoptosis and intracellular reactive oxygen species (ROS) levels. 
Additionally, peroxiredoxin-1 (PROX1) is one of the antioxidant enzymes and is involved in 
cellular proliferation and differentiation. The ability of PROX1 to enhance cell survival is 
traditionally attributed to its capacity to remove ROS68. Indeed, lower PROX1 activity 
increased levels of ROS and induced p53 expression. Therefore, the level of p53 is a major 
determinant of the effect of decreased PROX1 expression on tumor growth and the response 
of cells to treatment. This agrees with our results showing up-regulated p53 and down-
regulated PROX1 in arbutin-treated A375 melanoma cells. In addition to energy metabolism, 
arbutin may also affect nucleotide metabolism because ribonucleoproteins (HNRH1, ROA2, 
ROA1), ribonuclease inhibitor (RINI) and inosine-5’-monophosphate dehydrogenase 
(IMDH2) were affected by arbutin treatment. IMDH2 is a regulatory enzyme of guanine 
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nucleotide biosynthesis and is also strategically positioned in the metabolic pathway of 
thiopurines. Increased mRNA expression levels and enzymatic activity of IMPDH2 have 
been observed in rapidly proliferating tumor cells. IMDH2 has been established as an 
anticancer target. Therefore, downregulation of IMDH2 may suppress nucleotide 
biosynthesis, cell proliferation and malignancy of A375 melanoma cells. According to our 
proteomic results, many identified proteins, including heat shock proteins, glucose-
regulated proteins and other proteins, were found to be associated with p53, which is a 
major tumor-suppressor protein and plays significant roles in many biological processes in 
cancer development. Moreover, p53 has biological roles in pigmentation. Tumor suppressor 
p53 could down- and upregulate tissue-specific expression of the tyrosinase gene in human 
melanoma cell lines. Therefore, arbutin has potent effects on both protein and gene 
expression and leads to the suppression of melanogenesis and tumorigenesis of A375 
melanoma cells. However, the correlation of protein and gene expression with biological 
function will be further studied to better understand the effect of arbutin on the biology of 
A375 malignant melanoma cancer cells. In summary, we identified differentially expressed 
proteins in arbutin-treated A375 melanoma cells. Most of these proteins were key players in 
a wide variety of cellular processes, including cell proliferation, regulation of protein 
expression and signaling pathways. 
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